LYEL insider buying and SEC filings, explained
Lyell Immunopharma, Inc. · CIK 1806952
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$25.0M
Insiders who bought
2
Sold (not marked 10b5-1)
$608K
Planned sales (10b5-1)
$274
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Oct 12, 2026 | Sale | Jarrad Mattieu Aguirre (Chief Medical Officer) sold 422 shares at about $8.63 ($4K). Holdings down 2% to 19,857 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Oct 13, 2026, 5:17 PM ET |
| Sep 10, 2026 | Sale | David Shook (Chief Medical Officer) sold 500 shares at about $12.70 ($6K). Holdings down 2% to 20,423 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Sep 10, 2026 |
| Aug 21, 2026 | Sale | Gary K. Lee (Chief Scientific Officer) sold 1,457 shares at $15.54 ($23K). Holdings down 8% to 16,220 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Aug 25, 2026 |
| Aug 21, 2026 | Sale | Stephen J. Hill (President / COO) sold 989 shares at $15.54 ($15K). Holdings down 6% to 16,816 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Aug 25, 2026 |
| Aug 21, 2026 | Sale | Lynn Seely (CEO and Director) sold 9,589 shares at $15.54 ($149K). Holdings down 13% to 63,899 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Aug 25, 2026 |
| Aug 10, 2026 | Sale | Veronica Sanchez Bulis (VP, Corporate Controller) sold 621 shares at about $14.34 ($9K). Holdings down 4% to 14,799 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Aug 11, 2026 |
| Aug 10, 2026 | Sale | Gary K. Lee (Chief Scientific Officer) sold 131 shares at about $14.34 ($2K). Holdings down 1% to 17,677 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Aug 11, 2026 |
| Aug 10, 2026 | Sale | Stephen J. Hill (President / COO) sold 89 shares at about $14.34 ($1K). Holdings down <1% to 17,805 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Aug 11, 2026 |
| Aug 10, 2026 | Sale | Lynn Seely (CEO and Director) sold 390 shares at about $14.34 ($6K). Holdings down 1% to 73,488 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Aug 11, 2026 |
| Jul 17, 2026 | Planned (10b5-1) | Innovative Cellular Therapeutics Holdings Ltd (10% owner) sold 10 shares at $13.70 ($137), marked as a 10b5-1 plan trade. Holdings down <1% to 2,857,480 shares. | SEC filing Filed Jul 20, 2026 |
| Jul 16, 2026 | Planned (10b5-1) | Innovative Cellular Therapeutics Holdings Ltd (10% owner) sold 10 shares at $13.73 ($137), marked as a 10b5-1 plan trade. Holdings down <1% to 2,857,490 shares. | SEC filing Filed Jul 17, 2026 |
| May 11, 2026 | Sale | Veronica Sanchez Bulis (VP, Corporate Controller) sold 217 shares at about $18.91 ($4K). Holdings down 1% to 15,420 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jun 15, 2026 |
| May 11, 2026 | Sale | Gary K. Lee (Chief Scientific Officer) sold 130 shares at about $18.92 ($2K). Holdings down 1% to 17,808 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jun 15, 2026 |
| May 11, 2026 | Sale | Stephen J. Hill (President / COO) sold 89 shares at about $18.92 ($2K). Holdings down <1% to 17,894 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jun 15, 2026 |
| May 11, 2026 | Sale | Lynn Seely (CEO and Director) sold 388 shares at about $18.91 ($7K). Holdings down 1% to 73,878 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jun 15, 2026 |
| Jun 10, 2026 | Sale | David Shook (Chief Medical Officer) sold 1,977 shares at $12.64 ($25K). Holdings down 9% to 20,923 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jun 11, 2026 |
| Mar 6, 2026 | Purchase (code P) | ARCH Venture Fund IX, L.P. (10% owner) bought 488,090 shares indirectly at $25.61 ($12.5M), reported as a purchase (code P). Indirect holdings up 52% to 1,426,528 shares. Not marked as a 10b5-1 plan trade. Filed jointly with 4 other reporting owners. | SEC filing Filed Mar 9, 2026 |
| Mar 6, 2026 | Purchase (code P) | Paul L. Berns (10% owner) bought 488,090 shares indirectly at $25.61 ($12.5M), reported as a purchase (code P). Indirect holdings up 52% to 1,426,528 shares. Not marked as a 10b5-1 plan trade. Filed jointly with 8 other reporting owners. | SEC filing Filed Mar 9, 2026 |
| Feb 11, 2026 | Sale | Gary K. Lee (Chief Scientific Officer) sold 1,671 shares at about $23.39 ($39K). Holdings down 9% to 16,938 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 12, 2026 |
| Feb 11, 2026 | Sale | Stephen J. Hill (President / COO) sold 1,236 shares at about $23.39 ($29K). Holdings down 6% to 17,795 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 12, 2026 |
| Feb 11, 2026 | Sale | Lynn Seely (CEO and Director) sold 7,455 shares at about $23.39 ($174K). Holdings down 9% to 74,266 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 12, 2026 |
| Feb 10, 2026 | Sale | Veronica Sanchez Bulis (VP, Corporate Controller) sold 254 shares at $23.12 ($6K). Holdings down 2% to 15,637 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 11, 2026 |
| Feb 10, 2026 | Sale | Gary K. Lee (Chief Scientific Officer) sold 147 shares at $23.12 ($3K). Holdings down 1% to 18,609 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 11, 2026 |
| Feb 10, 2026 | Sale | Stephen J. Hill (President / COO) sold 109 shares at $23.12 ($3K). Holdings down 1% to 19,031 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 11, 2026 |
| Feb 10, 2026 | Sale | Lynn Seely (CEO and Director) sold 438 shares at $23.12 ($10K). Holdings down 1% to 81,721 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 11, 2026 |
| Dec 24–30, 2025 | Sale | Veronica Sanchez Bulis (VP, Corporate Controller) sold 2,072 shares between Dec 24, 2025 and Dec 30, 2025 at about $35.80 ($74K). Holdings down 22% to 7,141 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 6, 2026 |
| Nov 10, 2025 | Sale | Veronica Sanchez Bulis (VP, Corporate Controller) sold 239 shares at about $16.10 ($4K). Holdings down 3% to 9,213 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 12, 2025 |
| Nov 10, 2025 | Sale | Gary K. Lee (Chief Scientific Officer) sold 138 shares at $16.16 ($2K). Holdings down 1% to 15,366 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 12, 2025 |
| Nov 10, 2025 | Sale | Stephen J. Hill (President / COO) sold 95 shares at $16.12 ($2K). Holdings down 1% to 15,750 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 12, 2025 |
| Nov 10, 2025 | Sale | Lynn Seely (CEO and Director) sold 412 shares at $16.11 ($7K). Holdings down 1% to 67,159 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 12, 2025 |
19 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
2 insiders bought in 30 days
$25.0M in purchases since Mar 6, 2026 · Purchases traded Mar 6, 2026 to Mar 6, 2026 · Closed
| Insider | Value | Traded | Source |
|---|---|---|---|
| Paul L. Berns (10% owner) | $12.5M | Mar 6, 2026 | SEC filing |
| ARCH Venture Fund IX, L.P. (10% owner) | $12.5M | Mar 6, 2026 | SEC filing |
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow LYEL in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.